Archive

2: Pitch Deck Critique | April 10, 2024

Hey Pitchers – how confident are you in your delivery? What deck do you send for your first pitch? Are you sure it’s what investors want to see?

This one-hour Panel Discussion highlighted 5-10 top investors active in seed to late-stage deals. They critiqued and ranked three volunteer Club Member’s intro decks.

Each panelist shared what they hoped to see in an intro deck and how much time they are willing to give your idea.

Panelists (5)
Pooja Majmudar, PhD | Silicon Valley Bank
Sarah Benson-Konforty, MD | 1010VC
Kristin King, MBA | Boston Harbor Angels
Tari Suprapto | Novo Nordisk
Stella K. Vnook | Likarda

Pitchers
Amy Baxter | Pain Care Labs
Anna Argo | Cytotheryx, Inc.
Elizabeth Smith | Fzata

3: Pitch Deck Critique | April 17, 2024

Deal Makers deliver results for many different types of teams within life sciences. We introduced you to several who are building the path forward by bringing us together.

This one-hour Panel Discussion highlighted 16 top accelerators, associations, non-profits, strategics, government agencies and industry groups that bring partnerships together.

Each panelist shared their unique approach and value they offer to the market.

April Wurster | Snell & Wilmer
Elyse Blazevich | Colorado BioScience Association
Mackensie Vernetti | BIO
George Eastwood | Emily Whitehead Foundation
Rachael O’Meara | SIC Venture Studio
David  Crean | Biocom California
Prasun Mishra | American Association for Precision Medicine
Tamika Jackson | SSLS, Inc.
James Cavuoto | Neurotech Reports
Paula Norbom | Talencio
Geof Hannigan | Merck Digital Sciences Studio
Teresa Henry | Sequoia Biotech Consulting
Jack Florio | NuFund Venture Group
Laura Sailor | TheraXyte
Harsha Rajasimha | IndoUSrare
Michael Hill | Science Innovations, LLC
Merom Klein | Courage Growth Partners
Maarten Rotman | Mayo Clinic

4: Non-Dilutive Funding | April 24, 2024

Non-Dilutive Funding is the warmup exercise for many life science startups…and it can come from many different sources. It puts the technology players on the field to be evaluated by the scouts.

This one-hour Panel Discussion hightlighted 10+ top advisors, non-profits and government agencies that bring equity-free funding to some the world’s most exciting life science startups.

Each panelist shared their investment mandate, funding processes, deal structure preferences, and 12-month outlook.

Emily Caporello Bluvas | NINDS & NIH
Anton Xavier | Silicon Valley Bank
Maryam Ziaei | ARPA-H
Anthony Lozama | Novartis & NIH
Rachel Rath | Johnson & Johnson Innovation
Jess Hawthorne | CSC Leasing
Elaine Haynes | KaloCyte, Inc.
Vladimir Popov | Frederick National Laboratory
Michael Salgaller | NIH & NCI
Shawn Green | MTEC
Adam Koster | Interactome Bio
April Wurster | Snell & Wilmer
Phillip Ebner | JP Morgan

5: Angel Funding | May 1, 2024

Angels are the leadoff investors that pitchers face in the life sciences game. We heard what compels Angels to divinely invest early in promising technologies and people.

This one-hour Panel Discussion highlighted top Angel Investors willing to get the game started for some the world’s most exciting life science startups.

Each panelist shared their investment mandate, funding processes, deal structure preferences, and 12-month outlook.

Joshua J. Carson | Wisconsin Alumni Research Foundation (WARF)
Kenneth Chih-Wei Chen | bioSeedin
Rahul Garg | White Hole Hub
Michele Marzola | Italian Angels for Growth (IAG)
Kristin King, MBA | Boston Harbor Angels
Paul Grewal | SIC Venture Studio
Danny Smith | Christiaan & Company
Yaniv Sneor | Mid Atlantic Bio Angels
Keara Sauber | Sauber Capital

6: Venture & PE Funding | May 8, 2024

Venture Investors swing for the fences, driving startups across home plate and scoring massive returns. However, they only will take a swing at the perfect pitch.

This one-hour Panel Discussion highlighted top Venture Investors willing to take aggressive swings at the most exciting life science startups.

Each panelist shared their investment mandate, funding processes, deal structure preferences, and 12-month outlook.

Deborah Hemingway | Ecphora Capital
Skip Kelly | JPMorgan Chase & Co.
JoJo Platt | Platt & Associates, Inc.
Salvatore Buscemi | Brahmin Partners
Elena Itskovich | Nest Catalyst Ventures
Ben Kromnick | Mercury
Leen Kawas | Propel Bio Partners
Jenna Aronson | Two Bear Capital

7: Strategic Funding | May 15, 2024

Strategic Investors are seasoned experts that bring value to the strategy in play for the entities they support. Their investment may come in many different forms: seed funding, collaborations, licensing and M&A…just to name a few.

This one-hour Panel Discussion highlighted top Strategic Investors who take a calculated approach to funding the most exciting life science startups. Each panelist shared their investment mandate, funding processes, deal structure preferences, and 12-month outlook.

Anton Xavier | Silicon Valley Bank
Tari Suprapto | Novo Nordisk
Michael Hansen | Eppendorf
Tad Weems | Agilent Technologies
Stella Vnook | Likarda
Sami Yusuf | Mayo Clinic
Laura Hameed | CureDuchenne
Prasun Mishra | American Association for Precision Medicine
Trent Holland | Piper Sandler
James Zanewicz | Tulane University School of Medicine

8: Exits: M&A and IPO | May 22, 2024

In the end, the scoreboard is what matters. How your company exits matters to you, your investors and your partners. Set your vision on the endgame with help from the Bullpen.

This one-hour Panel Discussion will highlight top operators, brokers, investors and buyers who move life science startups across home plate. Each panelist shared their recent exits, the pathways they followed to get it done, deal structures, and 12-month outlook.

Nola Masterson | Portfolia Femtech Funds
Vered Gigi, PhD | aMoon Fund
Daniel Angius | Nasdaq
David Crean | Cardiff Advisory
Anne DeGheest | HealthTech Capital
Susan Grant Schneider | Sequoia Consulting
Chris Mayo | London Stock Exchange Group
Keara Sauber | Sauber Capital
Andy Danielsen | Mayo Clinic
Jeff Steinle | Fredrikson